



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	J-Lat GFP Cells (A72)
Catalog Number:	9856
Lot Number:	041218
Release Category:	C
Provided:	1 ml (1×10^7 cells/vial), viability is 90%. RPMI 1640 + penicillin G (100 U/ml) + streptomycin (100 µg/ml).
Cell Type:	Parental cell type: Jurkat Virally infected with the following packaged retroviral construct: LTR-GFP.
Propagation Medium:	RPMI 1640, 90%; FBS, 10%; supplemented with penicillin G (100 U/ml), streptomycin (100 µg/ml), L-glutamine (2 mM, 0.3 mg/ml).
Freeze Medium:	FBS, 90%; DMSO, 10%.
Growth Characteristics:	No special requirements, split 1:3 at 1×10^6 cells/ml. Cells grow in suspension, usually singly but some clumping has been noted.
Morphology:	Small, spherical cells in suspension. Morphology usually does not vary.
Sterility:	Negative for bacteria, mycoplasma, and fungi.
Special Characteristics:	Latently express GFP to varying degrees. Suited to study HIV latency and reactivation.
Recommended Storage:	Liquid nitrogen
Contributor:	Dr. Eric Verdin.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References:

Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. *EMBO J* **22**:1868-1877, 2003.

Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. *EMBO J* **20**:1726-1738, 2001.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: J-Lat GFP Clone A72 from Dr. Eric Verdin." Also include the references cited above in any publication.

These cells and methods of use are covered by US Patents 7,232,685 and 7,544,467.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact the J. David Gladstone Institutes, Email: veronica.viray@gladstone.ucsf.edu, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated

November 09, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.